Niagen Bioscience (NAGE) Cash & Equivalents (2015 - 2026)

Niagen Bioscience (NAGE) has 12 years of Cash & Equivalents data on file, last reported at $66.5 million in Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $66.5 million, up 19.66% year-over-year; the trailing twelve-month figure through Mar 2026 was $66.5 million (up 19.66% YoY), and the FY2025 annual result was $64.8 million, up 45.07% from the prior year.
• Cash & Equivalents grew to $66.5 million in Q1 2026 per NAGE's latest filing, from $64.8 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $66.5 million in Q1 2026 and troughed at $13.3 million in Q3 2022.
• A 5-year average of $36.4 million and a median of $27.6 million in 2024 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2022 and 2025: Cash & Equivalents tumbled 59.94% in 2022, then jumped 116.87% in 2025.
• A 5-year view of Cash & Equivalents shows it stood at $20.4 million in 2022, then surged by 33.68% to $27.3 million in 2023, then soared by 63.44% to $44.7 million in 2024, then soared by 45.07% to $64.8 million in 2025, then grew by 2.72% to $66.5 million in 2026.
• Business Quant data shows NAGE's Cash & Equivalents at $66.5 million in Q1 2026, $64.8 million in Q4 2025, and $64.3 million in Q3 2025.